164 related articles for article (PubMed ID: 33997749)
1. Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank.
Tavaglione F; De Vincentis A; Jamialahmadi O; Pujia R; Spagnuolo R; Picardi A; Morano S; Valenti L; Romeo S; Vespasiani-Gentilucci U
JHEP Rep; 2021 Jun; 3(3):100262. PubMed ID: 33997749
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank.
De Vincentis A; Tavaglione F; Spagnuolo R; Pujia R; Tuccinardi D; Mascianà G; Picardi A; Antonelli Incalzi R; Valenti L; Romeo S; Vespasiani-Gentilucci U
Int J Obes (Lond); 2022 Mar; 46(3):486-493. PubMed ID: 34750514
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
[TBL] [Abstract][Full Text] [Related]
4. A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores.
De Vincentis A; Tavaglione F; Jamialahmadi O; Picardi A; Antonelli Incalzi R; Valenti L; Romeo S; Vespasiani-Gentilucci U
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):658-673. PubMed ID: 34091049
[TBL] [Abstract][Full Text] [Related]
5. Liver Fibrosis Assessed Via Noninvasive Tests is Associated With Incident Heart Failure in a General Population Cohort.
Hydes TJ; Kennedy OJ; Glyn-Owen K; Buchanan R; Parkes J; Cuthbertson DJ; Roderick P; Byrne CD
Clin Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38723982
[TBL] [Abstract][Full Text] [Related]
6. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.
Angulo P; Bugianesi E; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Barrera F; Haflidadottir S; Day CP; George J
Gastroenterology; 2013 Oct; 145(4):782-9.e4. PubMed ID: 23860502
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
[TBL] [Abstract][Full Text] [Related]
8. Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis.
Vilar-Gomez E; Calzadilla-Bertot L; Wong VW; Castellanos M; Aller-de la Fuente R; Eslam M; Wong GL; George J; Romero-Gomez M; Adams LA
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):136-145.e6. PubMed ID: 32389886
[TBL] [Abstract][Full Text] [Related]
9. PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis.
Falleti E; Cussigh A; Cmet S; Fabris C; Toniutto P
Dig Liver Dis; 2016 Jan; 48(1):69-75. PubMed ID: 26493626
[TBL] [Abstract][Full Text] [Related]
10. Diabetes mellitus and the progression of non-alcoholic fatty liver disease to decompensated cirrhosis: a retrospective cohort study.
O'Beirne J; Skoien R; Leggett BA; Hartel GF; Gordon LG; Powell EE; Valery PC
Med J Aust; 2023 Oct; 219(8):358-365. PubMed ID: 37749902
[TBL] [Abstract][Full Text] [Related]
11. Modifiable lifestyle factors, genetic and acquired risk, and the risk of severe liver disease in the UK Biobank cohort: (Lifestyle factors and SLD).
Liu Z; Huang H; Xie J; Shen QE; Xu C
Dig Liver Dis; 2024 Jan; 56(1):130-136. PubMed ID: 37407315
[TBL] [Abstract][Full Text] [Related]
12. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis.
Ioannou GN; Splan MF; Weiss NS; McDonald GB; Beretta L; Lee SP
Clin Gastroenterol Hepatol; 2007 Aug; 5(8):938-45, 945.e1-4. PubMed ID: 17509946
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Severe Hypoglycemia Among Adults With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Lee JY; Kim YE; Han K; Han E; Lee BW; Kang ES; Cha BS; Ko SH; Lee YH
JAMA Netw Open; 2022 Feb; 5(2):e220262. PubMed ID: 35195697
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes.
Björkström K; Franzén S; Eliasson B; Miftaraj M; Gudbjörnsdottir S; Trolle-Lagerros Y; Svensson AM; Hagström H
Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2769-2775.e4. PubMed ID: 31009793
[TBL] [Abstract][Full Text] [Related]
15. Associations of severe liver diseases with cataract using data from UK Biobank: a prospective cohort study.
Chen C; Wei L; He W; Zhang Y; Xiao J; Lu Y; Wang F; Zhu X
EClinicalMedicine; 2024 Feb; 68():102424. PubMed ID: 38304745
[TBL] [Abstract][Full Text] [Related]
16. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
[TBL] [Abstract][Full Text] [Related]
17. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
18. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
19. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
[TBL] [Abstract][Full Text] [Related]
20. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank.
Walker RW; Belbin GM; Sorokin EP; Van Vleck T; Wojcik GL; Moscati A; Gignoux CR; Cho J; Abul-Husn NS; Nadkarni G; Kenny EE; Loos RJF
J Hepatol; 2020 Jun; 72(6):1070-1081. PubMed ID: 32145261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
